Skip to main content

Table 2 Characteristics of the TA patients stratified for therapy with PPIs and for the presence of arterial hypertension

From: Chromogranin-A production and fragmentation in patients with Takayasu arteritis

  Therapy with PPIs Arterial hypertension
  No (N = 12) Yes (N = 30) p value No (N = 20) Yes (N = 22) p value
Qualitative variables
 Sex (F:M) 11:1 28:2 n.s. 20:0 19:3 n.s.
 Class of arterial involvement:       
  1
  2A
  2B
  3
  4
  5
1
2
1
0
0
8
3
2
2
1
0
22
n.s.
n.s.
n.s.
n.s.
N.A.
n.s.
2
3
1
1
0
13
2
1
2
0
0
17
n.s.
n.s.
n.s.
n.s.
N.A.
n.s.
 Aneurysms 6 10 n.s. 7 9 n.s.
 Steroids 3 27 <0.001 13 17 n.s.
 Immunosuppressive therapy: 7 23 n.s. 11 19 0.04
 Biologic therapy:
  TNF blockers
  Tocilizumab
4
3
1
15
13
1
n.s.
n.s.
n.s.
10
9
1
9
7
1
n.s.
n.s.
n.s.
 Active disease (NIH criteria) 0 12 0.009 5 6 n.s.
 Anticoagulants 3 4 n.s. 3 4 n.s.
 Arterial hypertension 4 18 n.s. N.E. N.E.  
 Therapy with PPIs N.E. N.E.     
 Cardiac involvement 4 8 n.s. 6 6 n.s.
 Vascular enhancement (N = 30) 1 4 n.s. 3 2 n.s.
 Vascular progression (N = 40) 1 8 n.s. 5 4 n.s.
Scalar variables (median and range)
 Age (years) 51 (31–66) 41 (23–62) 0.060 40 (23–66) 47 (26–65) n.s.
 Age at TA onset (years) 36 (21–56) 28 (17–56) n.s. 29 (17–56) 30 (18–56) n.s.
 Disease duration (years) 12 (4–21) 9 (0–34) n.s. 9 (2–21) 11 (0–34) n.s.
 Creatinine (mg/dl) 0.70 (0.44–1.06) 0.70 (0.56–1.60) n.s. 0.67 (0.49–0.89) 0.75 (0.44–1.61) 0.084
 PDN dose (mg/day) 0 (0–12.5) 5 (0–35) <0.001 5 (0–25) 5 (0–35) n.s.
 N vessels 4 (1–6) 4 (1–7) n.s. 3 (1–-6) 4 (1–7) n.s.
 ESR (mm/h) 9 (1–23) 18 (2–78) 0.059 13 (2–73) 18 (1–78) n.s.
 Serum CRP (mg/l) 1.5 (0.1–12) 3.0 (0.3–40) 0.104 2.0 (0.1-40) 2.6 (0.3–36.8) n.s.
 Plasma PTX3 (ng/ml) 4.1 (1.3–44) 5.9 (2.2–55) n.s. 5.8 (2.5–43.6) 5.3 (1.3–55.0) n.s.
 CgAtot (nM) 1.02 (0.45–2.66) 3.40 (0.60–7.85) <0.001 1.35 (0.5–3-6.31) 3.76 (0.45–7.85) 0.021
 CgA439 (nM) 0 (0-0–19) 0.07 (0–0.78) n.s. 0.01 (0–0.44) 0.07 (0–0.78) n.s.
 CgA-FRs (nM) 0.76 (0.22–1.82) 2.18 (0.28–6.68) <0.001 0.89 (0.39–3.93) 2.45 (0.22–6.68) 0.030
 VS-1 (nM) 0.10 (0.02–0.34) 0.25 (0.06–1.15) 0.001 0.11 (0.02–0.79) 0.32 (0.05–1.15) 0.024
 CgA439/CgAtot 0 % (0–18 %) 2 % (0–24 %) n.s. 0 % (0–18 %) 2 % (0–24 %) n.s.
 CgA-FRs/CgAtot 69 % (50–84 %) 66 % (47–94 %) n.s. 69 % (50–84 %) 66 % (47–94 %) n.s.
 VS-1/CgAtot 12 % (1–24 %) 10 % (3–27 %) n.s. 12 % (1–24 %) 10 % (3–27 %) n.s.
 Rank CgA439+ rank VS-1 27 (5–50) 41 (18–83) 0.002 32 (5–64) 44 (8–83) 0.023
  1. Quantitative and qualitative variables related to TA were evaluated, verifying the impact of the treatment with PPIs and of arterial hypertension. N vessels refers to the number of vessels involved by the disease (see “Methods”)
  2. TA Takayasu arteritis, PPI proton-pump inhibitor, n.s. not significant, N.A. not available, TNF tumour necrosis factor, N.E. not evaluable, PDN prednisone, ESR erythrocyte sedimentation rate, CRP C-reactive protein, PTX3 pentraxin-3, CgA tot total chromogranin-A, CgA 439 full-length CgA (residues 1–439), CgA-FRs fragments of CgA spanning from the N-terminus to the central region but lacking the C-terminal region, VS-1 vasostatin-1